Common Contracts
2 similar Clinical Study Agreement contracts
ContractClinical Study Agreement • September 14th, 2020
CLINICAL STUDY AGREEMENT SMLOUVA O KLINICKÉ STUDII This Clinical Study Agreement (“Agreement”) is made and entered into as of 20-Dec-2016 (“Effective Date”) by and between, Ústav Hematologie a krevní transfuze located at U Nemocnice 2094/1, 128 20 Praha 2, Czech Republic (“Study Site”), located at U Nemocnice 2094/1, 128 20 Praha 2, Czech Republic (“Principal Investigator”), and Daiichi Sankyo, Inc., located at 399 Thornall Street, Edison, New Jersey 08837, USA (“DSI”). Study Site, Principal Investigator and DSI are each referred to as a “Party” and collectively as the “Parties.” Tato smlouva o klinické studii (dále jen„smlouva”) se uzavírá ke dni 20.12.2016 (dále jen „datum účinnosti”) mezi Ústav Hematologie a krevní transfuze na adrese U Nemocnice 2094/1, 128 20 Praha 2, Česká republika (dále jen „studijní pracoviště”), na adrese U Nemocnice 2094/1, 128 20 Praha 2, Czech Republic (dále jen „hlavní zkoušející”), a společností Daiichi Sankyo, Inc., se sídlem na adrese 399 Thornall
ContractClinical Study Agreement • May 5th, 2020
QUIZARTINIB/AC220 (the “Study Drug”); QUIZARTINIB/AC220 (dále jen „hodnocenýlék”); WHEREAS, the performance of the Study will benefit the Study Site and Principal Investigator and will further the Study Site’s and Principal Investigator’s goals of research,teaching, education and public service; and JELIKOŽ provádění studie bude ku prospěchu studijního pracoviště a hlavního zkoušejícího a dále podpoří cíle studijního pracoviště a hlavního zkoušejícího v oblasti výzkumu,výuky, vzdělávání a služeb veřejnosti; a WHEREAS, the Study Site and Principal Investigator have represented that they have the resources to perform the Study in acompetent manner, and in accordance with applicable law and industry practice. JELIKOŽ studijní pracoviště a hlavní zkoušející prohlásili, že mají k dispozici zdroje k odbornému provádění této studie v souladu s platnými zákony a zavedenou praxí v oboru; NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is her
